ClinicalTrials.gg
CompletedNCT00915915Updated Oct 28, 2014

Inhibition of Ovulation and Pharmacokinetics of Transdermal Ethinylestradiol (EE) and Gestodene (GSD)

A Phase 2 interventional study of Ethinylestradiol/Gestodene (BAY86-5016) and Ethinylestradiol/Gestodene (BAY86-5016) in Contraception and Ovulation Inhibition, sponsored by Bayer. Completed at 2 sites in Germany. Open to female participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-28.

Sponsored by Bayer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
Female
01

Study summary

Investigation of two transdermal hormone patch formulations for contraception regarding inhibition of ovulation over a period of 3 treatment cycles in healthy young female volunteers

02

Conditions studied

  • Contraception
  • Ovulation Inhibition

Keywords

  • Female contraception
  • Ovulation inhibition
03

In context

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • : 18 BMI 30 kg/m²
  • Healthy female volunteers
  • Age 18-35 years (smoker not older than 30 years, inclusive)
  • Ovulatory pre-treatment cycle, at least 3 month since delivery
  • Abortion or lactation before the first screening examination
  • Willingness to use non-hormonal methods of during entire study

Exclusion criteria

Exclusion Criteria:

  • for use of combined (estrogen/gestodene) (e.g. history of venous/artial thromboembolic disease
  • Regular intake of medication other than OCs
  • findings (blood pressure, physical and gynaecological examination, laboratory examination) anovulatory pre-treatment cycle
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
108 participants (actual)

Study arms

  • Experimental
    Arm 1

    Drug: Ethinylestradiol/Gestodene (BAY86-5016)

  • Experimental
    Arm 2

    Drug: Ethinylestradiol/Gestodene (BAY86-5016)

Interventions

  • DrugEthinylestradiol/Gestodene (BAY86-5016)

    Drug pages: Ethinyl Estradiol · Gestodene

    Transdermal patch: 0.55mg Ethinylestradiol (EE+2.1mg GSD)Gestodene; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles), 1 Follow - up cycle)

  • DrugEthinylestradiol/Gestodene (BAY86-5016)

    Drug pages: Ethinyl Estradiol · Gestodene

    Transdermal patch: 0.55mg Ethinylestradiol (EE+1.05mg GSD)Gestodene; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles), 1 Follow - up cycle)

06

What researchers measure

Primary outcomes

  1. The primary efficacy variable will be the proportion of volunteers with ovulation in at least one of the treatment cycles 2 and 3

    Time frame: 4 months

Secondary outcomes

  1. The primary efficacy variable will be the proportion of volunteers with ovulation in at least one of the treatment cycles 2 and 3

    Time frame: 4 months

  2. Course of gonadotropins (FSH, LH, P, E2)

    Time frame: 4 months

  3. Endometrial thickness and Follicle size

    Time frame: 4 months

  4. Pharmacokinetics of Ethinylestradiol (EE), Gestodene (GSD) and SHBG in treatment cycles 2 and 3

    Time frame: 4 Months

  5. Cervical effects (Insler Score) for determination of hormonal effects on the cervix and the cervical mucus during pre-treatment cycle and treatment cycle 3

    Time frame: 4 Months

07

Study locations

2 sites
  • Berlin, 10115, Germany
  • Berlin, 13353, Germany
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2009, a primary completion of Apr 2010 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2009
First posted
Jun 8, 2009
Start
Jun 2009
Primary completionActual
Apr 2010
CompletionActual
Apr 2010
Last update
Oct 28, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00915915
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jun 8, 2009
Start date
Jun 2009
Primary completion
Apr 2010
Completion
Apr 2010
Last update
Oct 28, 2014

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ethinyl Estradiol · Gestodene

Start the discussion